Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Bluebird Bio
(NQ:
BLUE
)
0.9228
+0.0103 (+1.13%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Bluebird Bio
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Why Is Zomedica (ZOM) Stock Up Today?
January 18, 2023
Zomedica (ZOM) stock is on the rise Wednesday after the company signed a strategic restructuring agreement with Qorvo Biotechnologies.
Via
InvestorPlace
Why Bluebird Bio (BLUE) Stock Is Getting Hammered
January 18, 2023
Bluebird Bio Inc (NASDAQ: BLUE) shares are trading lower by 10.0% to $6.55 Wednesday morning after the company announced a proposed public offering of common stock.
Via
Benzinga
Moderna (MRNA) Stock Pops on RSV Vaccine Trial Results
January 18, 2023
Moderna (MRNA) stock is on the move Wednesday alongside positive results from its latest Phase 3 mRNA-1345 vaccine trial.
Via
InvestorPlace
Moderna Gets Good News, but Another Biotech Stock Is Falling Again
January 18, 2023
The Nasdaq looked poised for modest gains once again on Wednesday.
Via
The Motley Fool
Why is Bluebird Bio (BLUE) Stock Down 9% Today?
January 18, 2023
Bluebird Bio (BLUE) stock is slipping on Wednesday after the biotechnology company announced a proposed public offering.
Via
InvestorPlace
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
January 18, 2023
Via
Benzinga
2 Risky Stocks That Could Soar in 2023
December 06, 2022
These "exciting" companies aren't for everyone.
Via
The Motley Fool
Looking Into bluebird bio's Return On Capital Employed
November 30, 2022
Via
Benzinga
Analyst Ratings for bluebird bio
November 08, 2022
Within the last quarter, bluebird bio (NASDAQ:BLUE) has observed the following analyst ratings:
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
January 18, 2023
We're starting the day with a breakdown of the biggest pre-market stock movers traders will want to watch on Wednesday morning!
Via
InvestorPlace
2 Stocks That Could Double Your Money in 2023
January 07, 2023
These biotechs could crush the market, but there is more to the story.
Via
The Motley Fool
Newly Approved Drugs In US Command Over $200,000 On An Average
January 05, 2023
The median annual price of 17 new drugs approved by the FDA since July 2022 reached $193,900, down from $257,000 in 1H of 2022. For the full year 2022, the median price was $222,003.
Via
Benzinga
1 Cathie Wood Stock to Buy While It's Affordable, and 1 to Avoid (for Now)
December 30, 2022
Both stocks have fallen brutally this year, but only one has a chance to recover soon.
Via
The Motley Fool
After Doubling in the Past 6 Months, Is This Stock a Buy?
December 24, 2022
This company has had a solid year, but there is still plenty of work ahead.
Via
The Motley Fool
Recap: bluebird bio Q3 Earnings
November 07, 2022
bluebird bio (NASDAQ:BLUE) reported its Q3 earnings results on Monday, November 7, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
FDA Allows Bluebird Bio To Resume Sickle Cell Disease Studies In Patients Below 18, With Changed Protocol
December 19, 2022
Via
Benzinga
BLUE Stock Alert: What to Know as the FDA Lifts Hold on Bluebird Bio Treatment
December 19, 2022
In a counterintuitive move, traders are selling BLUE stock even as Bluebird Bio claims to be on track with its sickle cell disease treatment.
Via
InvestorPlace
Magenta Therapeutics Shares Surge After Encouraging Data From Blood Cancer Candidate At ASH Meeting
December 13, 2022
Via
Benzinga
Why Bluebird Bio Stock Crushed the Market Today
December 12, 2022
The company looks set to continue its good momentum in the early part of next year.
Via
The Motley Fool
What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers
December 06, 2022
By Ernest Dela Aglanu, Benzinga
Via
News Direct
Bluebird Bio Sells Priority Review Voucher For $102M, Strengthening Its Financial Position
November 30, 2022
Via
Benzinga
FDA Approves UniQure's Hemgenix, First Hemophilia B Gene Therapy For Adults
November 23, 2022
Via
Benzinga
Where Will Editas Medicine Be in 1 Year?
November 20, 2022
The company could continue lagging the market for a while.
Via
The Motley Fool
2 Growth Stocks That Could Double in 2023
November 17, 2022
Both are lagging the market this year.
Via
The Motley Fool
Spirit AeroSystems, Oyster Point Pharma, Snap And Other Big Gainers From Monday
November 08, 2022
U.S. stocks closed higher on Monday, with the Dow Jones surging more than 400 points. Here is the list of some big stocks recording gains in the previous session.
Via
Benzinga
Better Buy: CRISPR Therapeutics vs. Bluebird Bio
October 27, 2022
These two companies have performed almost equally poorly on the stock market in the past year.
Via
The Motley Fool
Why Huadi International Group Shares Dipped Around 91%; Here Are 79 Biggest Movers From Yesterday
November 08, 2022
Gainers
Via
Benzinga
What's Next For Cell Therapy In Oncology? Enlivex (NASDAQ: ENLV) Says It Has The Answers
October 25, 2022
Since Robert Hooke discovered cells in 1665 and Theodor Schwann proposed the classical cell theory in 1839, the cell therapy industry has grown by leaps and bounds.
Via
Benzinga
Why Legend Biotech's Shares Jumped 14.2% On Tuesday
October 18, 2022
The company presented news regarding early revenue figures for a multiple myeloma therapy it collaborated on.
Via
The Motley Fool
Biotech Stocks Well-Positioned For The Fourth Quarter
October 12, 2022
The path of interest rates is clearer for 2022 and the FED is closer to a pause early next year as it calibrates its response from a hammer approach so far.
Via
Talk Markets
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.